These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 11977396

  • 1. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E, Illiger HJ.
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract] [Full Text] [Related]

  • 2. Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
    Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F, Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A.
    Breast Cancer Res Treat; 2011 Feb; 125(3):775-84. PubMed ID: 21132360
    [Abstract] [Full Text] [Related]

  • 3. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
    de Azambuja E, Paesmans M, Beauduin M, Vindevoghel A, Cornez N, Finet C, Ries F, Closon-Dejardin MT, Kerger J, Gobert P, Focan C, Tagnon A, Dolci S, Nogaret JM, di Leo A, Piccart-Gebhart MJ.
    J Clin Oncol; 2009 Feb 10; 27(5):720-5. PubMed ID: 19103732
    [Abstract] [Full Text] [Related]

  • 4. [Radiation and concomitant chemotherapy after surgery for breast cancer].
    Calais G.
    Cancer Radiother; 2004 Feb 10; 8(1):39-47. PubMed ID: 15093200
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5166-70. PubMed ID: 16051958
    [Abstract] [Full Text] [Related]

  • 6. [Sequencing of chemotherapy and radiotherapy following breast-preserving treatment of breast carcinoma].
    Sauer R, Martus P.
    Strahlenther Onkol; 1996 Sep 01; 172(9):516-7. PubMed ID: 8928060
    [No Abstract] [Full Text] [Related]

  • 7. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E.
    Lancet; 1998 Aug 15; 352(9127):515-21. PubMed ID: 9716055
    [Abstract] [Full Text] [Related]

  • 8. Treatment of advanced breast cancer: How much chemotherapy is enough?
    DiPaola RS, Kaufman A, Mikhail MM.
    Semin Oncol; 1996 Jun 15; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
    [No Abstract] [Full Text] [Related]

  • 9. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoldi L, Camisa R, Bruzzi P.
    Cancer; 2002 Jul 15; 95(2):228-35. PubMed ID: 12124820
    [Abstract] [Full Text] [Related]

  • 10. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K.
    J Clin Oncol; 2003 Aug 15; 21(16):3066-71. PubMed ID: 12915595
    [Abstract] [Full Text] [Related]

  • 11. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
    Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G.
    Cancer; 2003 Jun 01; 97(11):2716-23. PubMed ID: 12767083
    [Abstract] [Full Text] [Related]

  • 12. [Adjuvant therapy of breast cancer].
    Semiglazov VF, Abzumanov AS, Bozhok AA, Ivanov VG, Ivanova OA, Barash NIu, Topuzov EE, Seleznev IK, Migmanova NSh, Popova RT, Nurgaziev KSh.
    Khirurgiia (Mosk); 2001 Jun 01; (5):52-60. PubMed ID: 11505673
    [No Abstract] [Full Text] [Related]

  • 13. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients.
    Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brünner N, Nauntofte B.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Aug 01; 106(2):217-26. PubMed ID: 18554960
    [Abstract] [Full Text] [Related]

  • 14. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B, Mouridsen HT, Jensen MB.
    Acta Oncol; 2008 Aug 01; 47(4):662-71. PubMed ID: 18465334
    [Abstract] [Full Text] [Related]

  • 15. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ.
    Clin Cancer Res; 2002 May 01; 8(5):1107-16. PubMed ID: 12006526
    [Abstract] [Full Text] [Related]

  • 16. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
    Kümmel S, Krocker J, Kohls A, Breitbach GP, Morack G, Budner M, Blohmer JU, Lichtenegger W, Elling D.
    Crit Rev Oncol Hematol; 2006 May 01; 58(2):166-75. PubMed ID: 16387512
    [Abstract] [Full Text] [Related]

  • 17. [A randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients].
    Sack H.
    Strahlenther Onkol; 1995 Jun 01; 171(6):360-1. PubMed ID: 7597623
    [No Abstract] [Full Text] [Related]

  • 18. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
    Battelli N, Massacesi C, Braconi C, Pilone A, Manzione L, Dinota A, Cobelli S, Scanni A, Sturba F, Giacomini G, Morale D, Giorgi F, Tummarello D, Cascinu S.
    Am J Clin Oncol; 2006 Aug 01; 29(4):380-4. PubMed ID: 16891866
    [Abstract] [Full Text] [Related]

  • 19. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K, TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Anticancer Res; 2002 Aug 01; 22(4):2325-32. PubMed ID: 12174922
    [Abstract] [Full Text] [Related]

  • 20. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK.
    J Natl Cancer Inst; 2008 Aug 06; 100(15):1058-67. PubMed ID: 18664656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.